Humacyte Announces Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess® for Vascular Trauma Repair
Humacyte announced that the Israel Ministry of Health has accepted its Marketing Authorization Application for Symvess for arterial trauma repair. The Ministry assigned a 180-working-day review period for the application, citing the existing FDA approval in the U.S. as a basis.
Key figures
- Drug Name
- Symvess
- Review period
- 180-working-day
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.